The present study demonstrated that early adjunctive therapy with PCSK9 inhibitor evolocumab significantly reduced the incidence of END within 7 days and suppressed the elevation of the plasma IL-6 concentrations in patients with AIS, whereas there were no significant changes in peripheral blood T lymphocyte subsets in this trial. This evidence concerns the gene IL6 and androgen insensitivity syndrome.